MAPT and Mental deterioration: Another argument for the potential benefit of anti-amyloid and tau combination therapy is the limited impact of anti-amyloid antibodies [3], when administered later in the disease course, on measurable biomarkers of tau pathology, which are closely correlated to cognitive decline [25].